8 years ago

Macrophage Pharma Extends Series A with Investment from Merck Ventures

  • Macrophage Pharma, a UK-based immuno-oncology company focused on macrophage modulation in the tumor microenvironment (TME), has secured additional funding from Merck Ventures to complete its Series A financing

  • This investment builds upon the existing investor syndicate which includes CRT Pioneer Fund (CPF), Novo Holdings A/S, and Aglaia Biomedical Ventures BV

  • The funding will enable Macrophage Pharma to advance its lead development candidate, a macrophage-targeted p38MAP kinase inhibitor, towards clinical trials and further develop two additional discovery candidates

  • The company is also planning to add a fourth macrophage-targeted project to its pipeline

  • Macrophage Pharma is focused on developing next-generation immunotherapies for various cancers using its ESM™ technology platform.

      • ProblemHealthcare

      "Cancer is a leading cause of death worldwide. Current treatments can be ineffective and have severe side effects."

      Solution

      "Macrophage Pharma is developing a new type of immunotherapy that targets macrophages in the tumor microenvironment. Their ESM™ technology platform delivers small molecule drugs to macrophages, activating the body’s natural immune system to fight cancer. This approach aims to be more effective and have fewer side effects than current treatments."

      Covered on